Abstract Library

#620 Multicenter Retrospective Analysis of Systemic Chemotherapy for Advanced Poorly Differentiated Neuroendocrine Carcinoma of Digestive System

Introduction: No standard chemotherapy is established for advanced poorly differentiated neuroendocrine carcinoma (PDNEC) originating from the gastrointestinal tract (GI) or the hepato-biliary-pancreatic system (HBP).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Tomohiro Y

Authors: Yamaguchi T, Machida N, Kasuga A, Takahashi H, Sudo K,

Keywords: poorly-differentiated, PDNEC, irinotecan, etoposide, gastrointestinal,

#323 Efficacy and Safety of Everolimus in Japanese Patients With Advanced Pancreatic Neuroendocrine Tumors (pNET): Japanese Subgroup Analysis of RADIANT-3

Introduction: Everolimus, an oral inhibitor of mTOR, significantly improved progression-free survival (PFS) v. placebo in a phase III trial (RADIANT-3) in patients with advanced pNET.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Okusaka T, Ito T, Ikeda M, Tajima T, Kasuga A,

Keywords: mTOR, everolimus, octreotide LAR, neuroendocrine tumor,